Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment

“…As a result, the use of specialized viability assays, specifically designed for 3D in vitro models, is of great relevance to accurately assess the overall viability of organoid cultures. The previously introduced CTG-3D luminescent assay is the most widely used method in organoid studies [ 148 , 149 , 150 , 151 ].…”

Microfluidics: a concise review of the history, principles, design, applications, and future outlook

“…227 This showed that stem cells can self-organize into organoids that resemble native organs. At present, researchers can cultivate organoids derived from stem cells that mimic the physiological attributes of diverse human organs like blood vessels, 228 kidneys, 229,230 pancreas, 231 lungs, 232,233 intestine 234 and brain. 235,236 These replicas find applications in emulating genetic disorders, advancing personalized medicine, conducting drug tests, and investigating the roots of diseases.…”

Moving toward precision medicine with lung cancer organoids

“…In this context, Wang et al. 1 set out to test the ability of LCOs to predict clinical efficacy of clinically used targeted therapy and chemotherapy agents in affected individuals. The authors generated a large biobank of 160 LCOs, 132 of which were from malignant serous effusions, the specimen source with a high, 82%, success rate.…”

“…The study of Wang et al. 1 demonstrates the feasibility of using LCOs to tailor an affected individual’s therapeutic regimens according to their cancer’s in vitro responses. As part of this, it is crucial to note that LCOs can be “bio-banked,” which will allow sharing of these resources between labs that, in turn, will provide a great experimental validation “force multiplier.” Thus, the future is open for the development of additional methods, assays, and clinical correlative data for LCOs to eventually facilitate their entrance into routine clinical care.…”

“… In this issue of Cell Reports Medicine, Wang et al. 1 generated 160 human lung cancer organoids, primarily from malignant effusions, and tested their responses to clinically used drugs to determine whether the ex vivo organoid responses predicted patient responses. …”